Trials / Completed
CompletedNCT00401115
Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
A Phase 1, Open-Label, Dose-Escalation Clinical Study to Assess the Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Santen Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MS-R001 (rapamycin) | Subconjunctival injection in various dosages |
| DRUG | MS-R001 (rapamycin) | Intraocular injection in various dosages |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-11-17
- Last updated
- 2010-07-26
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00401115. Inclusion in this directory is not an endorsement.